Newsletter Subject

Promise and perils of AI medicine

From

bloombergbusiness.com

Email Address

noreply@mail.bloombergbusiness.com

Sent On

Wed, Aug 15, 2018 11:06 AM

Email Preheader Text

From    Hi folks, it’s Jeremy from London. There’s no hotter technology right now th

[Bloomberg] [Fully Charged]( From [Bloomberg](   [FOLLOW US [Facebook Share]]([Twitter Share]( [SUBSCRIBE [Subscribe]](  Hi folks, it’s Jeremy from London. There’s no hotter technology right now than artificial intelligence. And one of the areas where people are most hyping its promise is medicine. Hardly a day passes without an announcement about AI software that can read medical imagery better than radiologists, [arrive at diagnoses]( from a description of symptoms better than doctors or scrutinize hospital schedules to [slash waiting-room times](. This, in turn, has people speculating about the future of human doctors: venture capitalist Vinod Khosla went so far as to [claim]( radiologists would be obsolete by 2022. Well, on Monday, it was DeepMind’s [turn](. The AI company, owned by Google parent Alphabet, is best known for AlphaGo, the software that beat the world’s top humans at Go. DeepMind, which has a whole division devoted to health care, published a paper with NHS researchers showing that software they had developed can diagnose 50 sight-threatening eye conditions as well, or better than experts. DeepMind and its NHS partners seem to have gone out of their way to ensure the science was done right: publishing in a peer-reviewed journal, carefully curating and cleaning the data used to train the software, and building a system that let doctors gain insights into how the software made its assessments. They're planning full clinical trials before rushing a product to market. Unfortunately, the same cannot be said of many of the claims being made about AI in medicine, much less some of the AI-enabled health-care products already on the market. In fact, to date, despite all the hype, there have only been 14 peer-reviewed publications involving computer-vision software interpreting medical imagery, according to a [running tally]( maintained by the cardiologist and medical writer Eric Topol. So far there's been only one — one! — peer-reviewed study of a prospective trial, a study using AI to spot small polyps in colonoscopy images in real-time. But, as Topol notes, this hasn't stopped the U.S. FDA from approving AI-enabled products – it has greenlit 13 so far, most of which haven’t published peer-reviewed research on their software’s performance. While the FDA does have a rigorous approval process, the fact outside medical researchers and the wider public haven’t been able to scrutinize the science behind these products could be worrisome. Troubling questions have been raised about some highly-touted AI medical products. Last month, medical website Stat [reported]( it had obtained internal documents showing that IBM’s Watson for Oncology product sometimes provided “unsafe and incorrect” treatment recommendations. London-based digital health company Babylon, to take another example, has made bold claims about its AI-driven chatbot, saying the symptom checker can outperform the average GP on questions designed to test diagnostic ability. (The company says its bot provides “health information” not “diagnoses,” because it is not yet regulator-approved as a medical device.) But a doctor [complained](to the U.K. medical product regulator that the bot failed to pick up on symptoms associated with a heart attack. Babylon said it has answered the MHRA’s questions and isn't currently under investigation. There are big potential pitfalls with using AI to analyze medical imagery as well. John Zech, a doctor at the California Pacific Medical Center, recently [wrote]( that he and other researchers had discovered computer vision software trained to spot an enlarged heart or pneumonia on chest X-rays might actually just be homing in on other data in the image.  For instance, the AI paid a lot of attention to lettering on the X-rays indicating whether it had been taken with a portable X-ray machine or a full-size one. That’s because portable X-rays are more likely to be used with sicker patients. Marks like this are present on many of the images in the sets of anonymized chest X-rays released by the U.S. National Institutes of Health to help train AI systems. In fact, Zech isn't the only doctor to raise issues with the quality of the NIH data. Other researchers have [found]( problems with how many of the images are labeled. Yes, artificial intelligence may one day transform medicine. That day may even be dawning now. But, for the moment, the best prescription when reading about AI beating human doctors is probably this: take once daily with a giant pinch of salt.  And here’s what you need to know in global technology news China is cracking down on video games. Politics in China is putting approval of many games [on hold](. Tencent’s stock is slumping after regulators told the games distributor to remove Monster Hunter: World from its PC downloads service just [days after the action title’s debut](.  Another Intel chip flaw? The company says a limited number of server computers would be [at risk](to an exploit that would be extremely difficult to implement, but Intel’s stock dipped anyway.  Not a good match. A spat between Tinder’s founders and IAC is [getting uglier](, with  founders, executives and early employees suing IAC/InterActiveCorp and Match Group for at least $2 billion.   Sponsored Content by [monday.com]( The next generation of project management tool is here. [monday.com]( offers simplified planning and visual collaboration tools that let you assign teammates to specific tasks and create customizable boards to track everything your team is working on. Never lose track again. [Create your free account.](   You received this message because you are subscribed to the Bloomberg Technology newsletter Fully Charged. You can tell your friends to [sign up here](.  [Unsubscribe](%7Boptout_confirm_url%7D) | [Bloomberg.com]( | [Contact Us]( Bloomberg L.P. 731 Lexington, New York, NY, 10022 If you believe this has been sent to you in error, please safely [unsubscribe](.

Marketing emails from bloombergbusiness.com

View More
Sent On

20/07/2024

Sent On

19/07/2024

Sent On

19/07/2024

Sent On

19/07/2024

Sent On

19/07/2024

Sent On

18/07/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.